Sage changes main endpoint in Huntington's study months ahead of readout

Max Gelman

Senior Editor

Sage Therapeutics is altering the primary endpoint of a Phase 2 study for its drug candidate dalzanemdor in cognitive impairment associated with Huntington’s disease, just …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sage changes main endpoint in Huntington's study months ahead of readout

Max Gelman

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

Roivant makes another deal, selling Dermavant to Organon for up to $1.2B

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Breaking down silos with a new quantitative approach to drug development

Sage changes main end­point in Hunt­ing­ton's study months ahead of read­out

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Sage changes main endpoint in Huntington's study months ahead of readout